Medications Affecting PAC/PRA Ratio and Plasma Metanephrines
For PAC/PRA ratio testing, withdraw mineralocorticoid receptor antagonists (MRAs), potassium-wasting diuretics, and amiloride/triamterene for at least 4 weeks; withdraw β-blockers, ACE inhibitors, ARBs, α-2 agonists, and dihydropyridine calcium channel blockers for at least 2 weeks; and use α-1 blockers (doxazosin), hydralazine, or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) for blood pressure control during testing. 1, 2
Drugs Affecting PAC/PRA Ratio
Must Withdraw (4+ weeks before testing):
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) - raise both renin and aldosterone, causing false negatives 1, 2, 3
- Potassium-wasting diuretics (thiazides, loop diuretics) - raise renin and aldosterone, causing false negatives 1, 2, 3
- Potassium-sparing diuretics (amiloride, triamterene) - raise renin, causing false negatives 1, 2
Should Withdraw (2 weeks before testing):
- β-blockers - lower renin more than aldosterone, causing false-positive elevated ARR 2, 3, 4
- ACE inhibitors - raise renin, potentially causing false negatives (though detectable renin on these drugs doesn't exclude PA) 2, 3
- ARBs - raise renin, potentially causing false negatives 2, 3
- α-2 agonists (clonidine, methyldopa) - lower renin and aldosterone, causing false-positive elevated ARR 2, 3
- Dihydropyridine calcium channel blockers - variable effects on renin 1, 2
Safe to Continue (minimal interference):
- α-1 blockers (doxazosin, prazosin, terazosin) - recommended for blood pressure control during testing 1, 2
- Hydralazine - minimal effect on renin-aldosterone axis 1, 2
- Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) - minimal effect on ARR 1, 2, 5
Additional Interfering Medications:
- NSAIDs - lower both renin and aldosterone through sodium retention, causing false-positive elevated ARR 2, 6, 3
- Oral contraceptives (estrogen-containing) - increase aldosterone and decrease direct renin concentration (DRC) but not plasma renin activity (PRA), causing false positives when using DRC 2, 6, 2
- Drospirenone (progestin with MRA activity) - raises both renin and aldosterone 6, 3
- SGLT2 inhibitors - raise renin 3
Drugs Affecting Plasma Metanephrines
Medications Causing False Positives:
- Tricyclic antidepressants - interfere with catecholamine disposition, causing elevated metanephrines 7
- β-blockers - can trigger hypertensive crises in pheochromocytoma patients 1, 8
- Monoamine oxidase inhibitors (MAOIs) - can trigger hypertensive crises 1, 8
Analytical Interference:
- Acetaminophen - interferes with LC-ECD measurement methods 7
- Mesalamine and sulfasalazine - interfere with LC-ECD measurement methods 7
Critical Testing Considerations
For PAC/PRA ratio: Blood must be drawn in the morning after the patient has been upright for at least 2 hours, then seated for 5-15 minutes. Correct hypokalemia with potassium chloride (not bicarbonate-generating supplements) before testing, as low potassium suppresses aldosterone secretion and causes false negatives 1, 2.
For plasma metanephrines: Draw blood after the patient has been supine for at least 30 minutes to minimize false positives from physiological stress 7. If measuring 3-methoxytyramine, obtain samples after an overnight fast 7.
Common Pitfalls
The most frequent error is testing patients on β-blockers or diuretics without recognizing their impact on ARR. β-blockers suppress renin disproportionately, creating false-positive elevated ratios in patients without primary aldosteronism 2, 4. Conversely, ACE inhibitors and ARBs raise renin, potentially masking primary aldosteronism—though undetectable renin despite these medications strongly suggests autonomous aldosterone production 2.
For pheochromocytoma screening, never use β-blockers without α-blockade first, as unopposed α-stimulation can precipitate hypertensive crisis 1, 8.